Incyte (INCY) Exchange Rate Effect (2016 - 2026)
Incyte's (INCY) quarterly Exchange Rate Effect came in at -$84000.0 in Q2 2026, up 92.98% YoY from -$43527.3 in Q2 2025, and up 96.88% on a QoQ basis from -$2.7 million in Q1 2026.
Powered by 
Analysis
Incyte (INCY) Exchange Rate Effect (2016 - 2026) Analysis & Trends
Incyte (INCY) has 11 years of Exchange Rate Effect data on file, last reported at -$84000.0 in Q2 2026.
- Quarterly Exchange Rate Effect rose 92.98% year-over-year to -$84000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$2.7 million (down 248.78% YoY) and the FY2025 annual result came in at -$1.7 million, down 158.47% from the prior year.
- Exchange Rate Effect climbed to -$84000.0 in Q2 2026, from -$2.7 million in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $3.5 million in Q4 2024 to a low of -$7.3 million in Q4 2023.
- A 5-year average of -$271111.1 and a median of -$35500.0 in 2024 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 557.03% in 2025, down 9307.69% in 2025.
- Tracing INCY's Exchange Rate Effect over 5 years: stood at $627000.0 in 2022, then tumbled by 1264.43% to -$7.3 million in 2023, then jumped by 147.36% to $3.5 million in 2024, then plunged by 123.16% to -$801000.0 in 2025, then soared by 89.51% to -$84000.0 in 2026.
- The last three Exchange Rate Effect figures came in at -$84000.0 (Q2 2026), -$2.7 million (Q1 2026), and -$801000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | -84,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -84,000.00 |
| Mar 31, 2026 | -2.69 Mn |
| Dec 31, 2025 | -801,000.00 |
| Sep 30, 2025 | 841,000.00 |
| Jun 30, 2025 | -1.20 Mn |
| Mar 31, 2025 | -552,000.00 |
| Dec 31, 2024 | 3.46 Mn |
| Sep 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Mar 31, 2024 | -676,000.00 |
| Dec 31, 2023 | -7.30 Mn |
| Sep 30, 2023 | 2.72 Mn |
| Jun 30, 2023 | -1.89 Mn |
| Mar 31, 2023 | -199,000.00 |
| Dec 31, 2022 | 627,000.00 |
| Sep 30, 2022 | 1.53 Mn |
| Jun 30, 2022 | 988,000.00 |
| Mar 31, 2022 | 210,000.00 |
| Dec 31, 2021 | 148,000.00 |
| Sep 30, 2021 | -1.56 Mn |